Compare Neurocrine Biosciences Inc (NBIX) vs Annaly Capital Management, Inc. (NLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Annaly Capital Management, Inc. — how do they compare? Neurocrine Biosciences Inc trades at $150 (market cap $15.91B), while Annaly Capital Management, Inc. trades at $23.38 (market cap $17.42B). The key difference: Neurocrine Biosciences Inc and Annaly Capital Management, Inc. are close in size by market cap, and Annaly Capital Management, Inc. pays a 12.98% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| NBIX | NLY | |
|---|---|---|
Market Cap | $15.91B | $17.42B |
Sector | Health | Financials |
52-Week High | $185.50 | $24.40 |
52-Week Low | $123.10 | $20.21 |
Enterprise Value | $15.92B | — |
Dividend Yield | — | 12.98% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $156.49, down 3.37% amid recent safety concerns over Vykat XR. The stock shows strong fundamentals with a P/E of 22.88, net income margin of 20.91%, and robust revenue growth. Technical indicators are bearish, with price near support at $155. Recent Q2 2026 earnings beat estimates, but Q3 expectations are high at $2.59 EPS.
Outlook remains positive due to strong analyst consensus (86.49% buy) and a $208.82 price target, though risks include drug safety issues and competitive pressures. Earnings growth and pipeline advancements offer upside, but volatility from news flow requires careful monitoring.
NLY trades at $23.39, up 1.08% today, with a bullish technical signal and consistent earnings beats in recent quarters. The stock shows strong profitability with a net income margin of 92.77% and ROE of 20.66%, supported by positive cash flow trends. Recent news highlights dividend announcements and upgrades, with Zacks ranking it a Strong Buy on July 29, 2026.
Outlook is positive given analyst consensus of $24.50 price target and 57% buy ratings, but risks include interest rate sensitivity and high leverage. Investment appeal lies in its 13%+ dividend yield and valuation below sector averages, though macroeconomic volatility could pressure returns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Annaly Capital Management, Inc.
Annaly Capital Management Inc is an American mortgage real estate investment trust. The company segments its operations into Residential and Commercial real estate investments. While Annaly's Residential assets are primarily comprised of agency mortgage-backed securities and debentures, it is primarily invested in commercial mortgage loans and mortgage-backed securities in its Commercial unit through its subsidiary, Annaly Commercial Real Estate Group. Agency mortgage-backed securities and debentures make up the majority of the company's overall portfolio. Most of the company's counterparties are located in the U.S. Annaly generates nearly all of its revenue from the spread between interest earned on its assets and interest payments made on its borrowings.
Read more on NLY →
